To describe blood conservation strategies for critically ill patients.
A nemia is a common problem in critically ill patients admitted to the intensive care unit (ICU) (1) (2) (3) (4) . The majority of critically ill patients are anemic at admission to the ICU. Hemoglobin concentrations typically decline by at least 0.5 g/dL/day during the first 3 days of ICU stay and continue to decline for patients with sepsis and higher severity of illness (1, 5) . This patient population may be at particular risk of adverse consequences from anemia given the cardiovascular, respiratory, and metabolic compromise frequently encountered during critical illness. The etiology of the anemia is multifactorial, resulting from phlebotomy, gastrointestinal bleeding, coagulation disorders, blood loss from vascular procedures, renal failure, nutritional de-ficiencies, bone marrow suppression, and impaired erythropoietin response (6) .
Red blood cell transfusion has traditionally been the most common corrective strategy for anemia in the ICU. Every year in the United States, approximately 11 million units of red blood cells are transfused to Ͼ3 million patients (7) . Approximately 30% to 37% of critically ill patients receive allogeneic red blood cell transfusions during their ICU stay (8, 9) and Ͼ40% of critically ill patients receive a transfusion at some point during hospitalization (1) .
The transfusion of blood components is increasingly scrutinized by healthcare providers, policy makers, and the public. Despite the efforts of local and national transfusion programs to protect against viral, bacterial, and prion transmission, new agents such as West Nile virus highlight the inability to guard against new or unexpected contagions. Additionally, noninfectious risks such as circulatory overload, acute and delayed transfusion reactions, microcirculatory dysfunction, and immune modulation remain serious potential side effects of transfusion (4, 7, 10, 11) . In Canada, the rising costs associated with specialized blood components and the introduction of measures to improve the safety and adequacy of the blood supply have contributed to a 51% rise in expenditures by the Canadian Blood Services during the past three yrs (Dr. Graham Sher, personal communication). Finally, healthcare providers and researchers have increasingly questioned the efficacy of transfusion to certain patient groups, particularly critically ill patients (1, 4, 11) .
To overcome the blunted erythropoietin response to anemia in critically ill patients, exogenous recombinant human erythropoietin has been investigated in a number of randomized, controlled clinical trials (12, 13) . Patients receiving erythropoietin are less likely to undergo transfusion, and these patients have greater increases in hemoglobin during their ICU stay. However, critically ill patients treated with erythropoietin may still require transfusion, and the cost effectiveness of recombinant human erythropoietin has yet to be established. From many perspectives therefore, the investigation of initiatives to improve blood utilization further and to reduce transfusion requirements is timely. A variety of strategies exist to help achieve this goal, including the administration of adequate nutritional support, avoidance of bone marrow toxins, erythropoietin stimulation of red blood cell production, consideration of therapy with blood substitutes, and minimizing blood loss because of diagnostic phlebotomy and bleeding. The use of several such comple-mentary strategies is likely to contribute to best practice in blood management in the ICU.
Methods
We searched the medical literature using the electronic databases of Medline (1966 ( -July 2003 , EMBASE (1980 EMBASE ( -2003 , CINAHL (1982 -August 2003 , the Cochrane database of systematic reviews (second quarter 2003), Cochrane central register of controlled trials (second quarter 2003), ACP Journal Club (1991 ( -April 2003 , database of abstracts of reviews and effects (second quarter 2003), and HealthSTAR (1975 ( -June 2003 . Search terms included the following: (point of care) and blood and (critical or intensive); (pediatric or neonatal) and (critical or intensive) and (blood or phlebotomy); (restrictive or conservation) and (critical or intensive) and (blood or phlebotomy); (waste or discard) and (critical or intensive) and (blood or phlebotomy); (standing or routine) and (critical or intensive) and (phlebotomy or blood); (normovolemic and hemodilution) and (critical or intensive); (salvage and blood) and (critical or intensive); and (threshold or trigger) and (critical or intensive) and transfusion. Strategies involving blood conservation techniques used in a critical care population were selected for qualitative description. Certain blood conservation strategies primarily used for other patient populations, but with potential generalizability and applicability to critically ill patients, were also described. Bibliographies and personal files were searched, and certain authors were contacted directly when information was incomplete.
Results and Data Summary
Contribution of Phlebotomy to Anemia of Critical Illness. Diagnostic phlebotomy may contribute substantially to the anemia that occurs in critically ill patients. Analysis of the amount of blood phlebotomized in the ICU varies according to the population studied, the length of stay evaluated, and the methodology of study. Previous descriptive studies of phlebotomy in the United States have found an average of 377 mL/day of blood phlebotomized in cardiothoracic ICUs, 240 mL/day in general surgical ICUs, and 41.5 mL/day in medical-surgical ICUs (14, 15) . A survey of ICUs in Great Britain found an average admitting day phlebot-omy of 85.3 mL, followed by an average daily phlebotomy of 66.1 mL (16) . More recently, a large observational study examining phlebotomy and transfusion practice in 145 European medicalsurgical ICUs found an average of 41.1 mL phlebotomized per day (1) . However, wide practice variation existed, and patients in nearly one half of participating ICUs had five or more blood samples drawn per day. A recent observational study of phlebotomy in German ICUs similarly found an initial median phlebotomy of 41.1 mL/day. The total amount of diagnostic blood loss was the most significant independent predictor of later transfusion (17) . Retrospective reviews of phlebotomy and transfusion practice at multidisciplinary tertiary American ICUs have revealed that phlebotomy accounts for approximately 50% of the variation in the amount of red blood cells later transfused (6, 14) . There also appears to be a significant positive correlation between severity of illness and both the number of blood draws and the total amount of blood phlebotomized per day (1, 18) , possibly placing the sickest patients at increased risk for worse anemia and the attendant risks of transfusion.
Risk Factors for Increased Iatrogenic Blood Loss and Phlebotomy
The mean frequency of phlebotomy in critically ill patients varies widely among published series, with a range between five and nearly two dozen samples per day (1, 5, 18) . Arterial blood gases are the most frequently ordered laboratory test in the ICU and may account for nearly 40% of blood phlebotomized in certain series (16, 19 -21) . The mean volume per draw depends on the particular blood test, the ICU, and clinical laboratory practice. Published estimates vary from 1.5 to 10 mL for arterial blood gas and from 4 to 10 mL for hematology, coagulation, and chemistry samples (1, 5, 16) . The mean volume per draw in the most recent and largest series to date was 10.3 mL (1).
In addition to blood lost because of arterial or venous test amounts, patients with in-dwelling arterial catheters are subject to more frequent blood draws (being phlebotomized twice as often) and have a three-fold increase in phlebotomy volume compared with patients without such catheters (14, 6, 18) . Similarly, the presence of a central venous catheter is associated with a three-fold increase in blood loss through diagnostic phlebotomy compared with patients who do not have such intravenous access (16) . Blood chemistries constitute the majority of blood volume drawn. The presence of an elevated Acute Physiology and Chronic Health Evaluation II score, elevated Sequential Organ Failure Assessment score, central venous catheters, and mechanical ventilation are also associated with increased phlebotomy (1, 16, 20) .
Although arterial and central venous catheters allow continuous hemodynamic monitoring and the infusion of vasoactive medications, the ease of phlebotomy afforded by such indwelling catheters may contribute to greater blood loss. Such catheters should be discontinued when no longer required for physiologic monitoring or medication administration. Limiting multiple daily sampling to sampling only when clinically justified may substantially decrease phlebotomy amounts. In addition, the need for arterial blood gas samples may be minimized by using continuous pulse oximetry to monitor SaO 2 in place of PaO 2 , and capnometry to monitor end-tidal CO 2 in place of PaCO 2 , when such measurements are well correlated (21) (22) (23) .
Blood Discarded When Performing Diagnostic Phlebotomy
Each blood draw taken via an arterial, central venous, or large-bore catheter results in a variable amount of the initial phlebotomy that is discarded to clear the catheter of infusate that may affect the accuracy of the laboratory results. This volume depends on local medical and nursing practice; published reports vary from 2 to 10 mL of discarded "blood" (5, 24 -26) . A discard volume of only twice the catheter dead-space is adequate (27); 2 mL is generally recommended for accurate and reproducible arterial blood gas measurement and approximately 1-2 mL for most blood chemistries (28).
By using a closed method of blood sampling and returning the initial sample component to the patient, such "wasting" of blood can easily be eliminated. Numerous groups have described techniques for closed sampling using an inline 5-10 mL syringe attached to a three-way stopcock positioned nearest the patient ( Figs. 1  and 2 ). An initial diluted sample is drawn from the patient into the syringe, corresponding to the amount that usually would be wasted. The stopcock is reposi-tioned, and the diagnostic sample is obtained in another syringe. The initial sample is then reinfused into the patient, and the catheter can be flushed clear (24, 29, 30) . When evaluating this technique in a small randomized, controlled clinical trial of critically ill surgical patients, the use of a closed arterial system decreased the mean phlebotomy amount by 50% (24) . A subsequent study demonstrated similar reductions in wasted blood and hemoglobin decline in patients treated with the closed system (28). Patients in the closed-system groups were also transfused to a nonsignificantly lesser degree. Such a system might be particularly effective when used for patients with increased severity of illness and frequent phlebotomies. Truly closed systems that minimize opening and closing of access ports may also lessen the risk of bacterial colonization of catheter hubs and the subsequent risk of catheter-related bloodstream infections. When reinfusing the initial sample and clearing the catheter, a slow rate of fluid return (Ͻ1 mL/sec) should avoid the risk of retrograde arterial embolization. Several closed sampling systems are available commercially that may be easily connected in series with indwelling arterial or central venous catheters.
Small-Volume Phlebotomy Tubes and Point-of-Care Bedside Microanalysis
It has long been recognized that diagnostic phlebotomy can lead to anemia in critically ill patients. This risk may be greatest for critically ill neonatal and pediatric patients. Accordingly, smallest volume phlebotomy and blood conservation are widely practiced in most pediatric ICUs (31). Several investigators have studied the use of small-volume or pediatric phlebotomy tubes for critically ill adults. The use of pediatric tubes was compared with regular blood collection tubes, finding a 42% decrease in blood loss with the smaller tubes. There were no adverse outcomes and only one instance (of 432 chemistry specimens) of insufficient volume for the tests ordered (32). Previous studies evaluating a combination of small blood tubes and staff education were also found to reduce blood loss by roughly one half (15, 33) .
Bedside diagnostic testing using very small phlebotomy volumes is becoming increasing common in the ICU as the necessary technology becomes more reliable and affordable. Point-of-care blood analysis often requires sample volumes Ͻ0.5 mL, has a turn-around time of minutes, and generally involves less personnel time. Portable bedside blood glucose analyzers are used in many settings (34). Bedside arterial blood gas and electrolyte analyzers are also common and have been shown to correlate with simultaneous laboratory-based analysis (35, 36). Accuracy and precision for hematocrit, hemoglobin (37), and coagulation studies may be more variable, depending on the device and clinical circumstances (38, 39). Inline diagnostic blood testing allows for continuous sampling and analysis of blood chemistry (40). As this technology matures, its use may allow for even greater reductions in diagnostic blood loss.
The potential benefits of point-of-care testing must be weighed against potential liabilities (41, 42). The difference in costs between centralized laboratory-based testing and satellite laboratory or pointof-care testing must be examined in each institution. Start-up costs for point-of-care technology in an ICU involve acquisition costs for multiple bedside or ICUbased analyzers, information technology upgrades to allow entry of laboratory results into the electronic or paper medical record, and ongoing costs of individual disposable cartridges. Additionally, an ongoing program of quality assurance and calibration must ensure strong correlation between point-of-care and clinical laboratory results. Potential laboratory cost savings are more difficult to immediately quantify, as many central laboratory costs are fixed and annualized, or indirect, with very low per-sample costs. There may be savings in costs for personnel required to transport and process the high volumes of samples from many ICUs (43, 44) .
Red Blood Cell Salvage Techniques
Intraoperative blood recovery is a common means of blood transfusion for procedures routinely associated with significant surgical bleeding (10) . Postoperatively, blood can also be recovered from surgical drains and then reinfused, with or without processing, to the patient. Because such blood is often diluted, partially hemolyzed, defibrinated, and may contain a high concentration of cytokines, the effectiveness of routine salvage techniques has been uncertain (10, (45) (46) (47) (48) (49) . Selective use of salvage and autotransfusion in critically ill patients with very large postoperative recoverable blood loss may be effective at limiting the acute development of anemia and transfusion requirements (50, 51) . Acute normovolemic hemodilution describes the removal of whole blood from a patient immediately before a surgical procedure and simultaneous replacement of circulating volume with a crystalloid or colloidal solution (10) . Whole blood is later transfused, after hemostasis has been reachieved. Although this practice before surgical procedures involving substantial blood loss has been extensively studied, it has not been evaluated among critically ill patients and is likely a much less feasible and effective technique for blood conservation.
Pharmacologic Hemostasis
Hemostatic agents are widely used to diminish postoperative bleeding, especially among critically ill patients who have recently undergone cardiac surgery. Meta-analyses do not demonstrate convincing evidence that desmopressin minimizes perioperative transfusion in patients who do not have congenital bleeding disorders (52) . However, the selected use of antifibrinolytic drugs, such as aprotinin, tranexamic acid, and epsilon aminocaproic acid, have been found to significantly diminish perioperative red blood cell transfusion and the need for reoperation because of bleeding, without serious adverse effects (53) . The generalizability of these findings to all medicalsurgical patients remains uncertain, but such drugs should be considered, along with correction of specific hemostatic defects and coagulopathies, when treating critically ill patients with serious bleeding events. Other biological agents and clotting factors such as activated factor VII are currently under investigation in specific subgroups of critically ill patients.
Appropriate Transfusion Thresholds
A number of clinical practice parameters for red blood cell and plasma transfusion have previously been developed to guide decisions about transfusion (54 -61) . Some of these guidelines have addressed concerns and controversies specific to the transfusion of critically ill patients. However, during the past decade, there has been increasing awareness of circumstances when red blood cell transfusion may not be associated with improved patient outcomes. Accompanying this concern, there has been a shift toward more restrictive transfusion and more conservative use of blood products (4, 11, 55, (62) (63) (64) . Many hospitals do not have a formal transfusion protocol, and there is considerable variability in the decisions of which critically ill patients, and at what hemoglobin threshold, should be treated or transfused (4, 65, 66) .
The Transfusion Requirements in Critical Care trial demonstrated that among most critically ill patients, a restrictive strategy of red blood cell transfusion (at a hemoglobin threshold of 7.0 g/dL) is at least as effective and possibly superior to a strategy of liberal transfusion (at a hemoglobin threshold of 10.0 g/dL) (4) . Despite this knowledge, a recent large observational study found that mean pretransfusion hemoglobin levels remain substantially higher (8.4 g/dL for all patients transfused, and 8.5 g/dL for those without active bleeding) (1) . Incorporating evidence-based transfusion protocols with strategies of blood conservation may further aid in eliminating inappropriate transfusion.
Prevalence of Blood Conservation Techniques
Although phlebotomy amounts can be dramatically reduced by the use of closed, no-waste sampling systems, small-volume phlebotomy tubes, and point-of-care analysis, these strategies are not widely practiced in adult ICUs. Studies of such strategies have either not evaluated or were of insufficient sample size to demonstrate a difference in the number of transfusions required. A survey of English and Welsh ICUs found that a closed arterial catheter system was used in only 18.4% of adult ICUs, compared with 67% of pediatric ICUs (67) . Additionally, only 9.3% of the adult ICUs surveyed were using small-volume or pediatric tubes for phlebotomy (67) . In a survey of nine Canadian university-affiliated ICUs, we discovered that very few ICUs are currently using any of the outlined blood conservation techniques; however, nearly all believe such techniques might be useful in preventing anemia. A larger survey is currently being conducted among all Society of Critical Care Medicine members to aid in determining the frequency and perceived utility of various strategies of blood conservation.
Interventions to Improve Blood Management Through Conservation
Multifaceted interventions, combining best evidence, strategies delivered by local opinion leaders and physician champions, coupled with audits of compliance, feedback and academic detailing, can be effective at changing physician and healthcare worker practice (68 -69) . The introduction of guidelines for the measurement of arterial blood gases in such a fashion has been found to achieve significant increases in appropriate requests for testing, increased adherence to the guidelines, decreases in the total number of arterial blood gases performed, decreases in blood phlebotomized, decreases in nursing resources, as well as decreases of direct and indirect ICU costs (21) .
We are currently performing a multifaceted intervention of blood conserva-tion and restrictive diagnostic phlebotomy, comparing usual practice with strategies combining small-volume phlebotomy tubes, point-of-care bedside microanalysis, closed no-waste sampling systems, elimination of "standing" daily repeat phlebotomies, iterative caregiver education, audit, feedback, and academic detailing. In an observational study of 89 consecutive critically ill patients at Stanford University, we found that diagnostic sample waste accounted for the most frequent and largest volume of blood loss, nearly twice as much blood loss as the most commonly ordered diagnostic tests. In a subsequent prospective controlled pilot clinical trial, introduction of a multifaceted blood conservation strategy resulted in an 87.5% reduction of initial sample discard, 40.5% reduction in complete blood cell count phlebotomy volume, 26.4% reduction in chemistry phlebotomy volume, and 31.2% reduction in coagulation phlebotomy volume, compared with the usual care group. Patients treated with the restrictive diagnostic phlebotomy and blood conservation strategy were also significantly less likely to receive packed red blood cell transfusions during their ICU length of stay.
Conclusions and Suggestions for Future Direction
We have identified numerous therapies that may aid in blood conservation and anemia prevention for critically ill patients. There are yet few randomized, controlled clinical trials to help us evaluate effectiveness. Intensivists might adopt certain interventions, such as the use of smaller volume phlebotomy tubes, as intuitive or obvious improvements on current practice. Such changes are often cost neutral and have limited potential for adverse effects. All outlined strategies deserve further evaluation in clinical tri-W e have identified numerous therapies that may aid in blood conservation and anemia prevention for critically ill patients. als according to accepted standards of therapy and technology evaluation (70) .
New therapies and diagnostic procedures must have both effectiveness and economic impact assessed in relation to the current standards of care. Comparator measures of effectiveness must minimally include measures of anemia (nadir hemoglobin or hematocrit during ICU length of stay, change in hemoglobin or hematocrit during ICU stay), transfusion requirements, other blood product requirements, and ideally, clinical outcome measures such as length of stay, complications, and mortality. Additionally, however, many of the therapies come at an increased cost. Formal economic evaluations of each therapy may help us to determine the best use of critical care resources as we strive to provide both effective and cost-effective blood management for critically ill patients. 
